B ACUTE LYMPHOBLASTIC LEUKEMIA

This large phase 3 trial studies whether different combinations and doses of chemotherapy can better control high-risk B acute lymphoblastic leukemia (B-ALL) in nearly 6,000 children and young adults. It also tests adding the targeted drug dasatinib for patients with specific gen…

This early-stage trial tests a combination of the oral drug venetoclax with standard chemotherapy and targeted therapies in adults with a specific, hard-to-treat leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see ho…

This study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (small amounts of cancer left after treatment). The drug attaches to a marker on cancer cells and delivers a toxin to kill them. The goal i…

This large study tests whether adding the drug blinatumomab to standard chemotherapy works better than chemo alone for children and young adults with newly diagnosed B-cell leukemia or lymphoma, including those with Down syndrome. The goal is to improve disease-free survival by h…

This early-stage study tests a treatment made from a patient's own immune cells, modified to recognize and attack cancer cells that have returned or not responded to standard therapy. The treatment is given with chemotherapy and an immune-boosting drug. The main goals are to chec…

This study tested a treatment plan for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). The approach combined an immunotherapy drug (blinatumomab) with standard chemotherapy or another targeted drug (dasatinib). The goal was to see i…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. Liver toxicity from the chemo drug asparaginase often delays treatment, especially in cert…

This study tests a targeted cancer drug (imatinib) with two different chemotherapy plans in children and teens newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a milder chemo regimen works just as well as a strong…

This early-stage study tests a new immune cell therapy for adults with a high-risk form of acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Doctors take a patient's own white blood cells, add a special gene to help them recognize and attack can…

This study compares a new treatment that combines a targeted drug (inotuzumab) with standard chemotherapy against chemotherapy alone for older adults with B-cell acute lymphoblastic leukemia or lymphoma. The targeted drug works like a smart bomb, attaching to cancer cells and del…

This early-stage trial tests whether a personalized cell therapy (CAR T-cells) can safely prevent relapse in older adults with B-cell acute lymphoblastic leukemia who are already in first remission. About 18 participants will receive their own immune cells, modified in a lab to t…